MVA-BN standard regimen

BIOLOGICAL2 trials

Sponsors

Jean-Pierre Van geertruyden

Conditions

ChildrenImmunogenicityInfantsMaternal TransmissionMpoxMpox (Monkeypox)NeonatePostpartum

Phase 3

Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC

Active, not recruitingNCT06844487

Jean-Pierre Van geertruydenChildren, Immunogenicity, Infants +3

Start: 2025-05-29End: 2027-05-01Updated: 2026-04-29

Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC

Active, not recruitingNCT06844500

Jean-Pierre Van geertruydenImmunogenicity, Maternal Transmission, Mpox +5

Start: 2025-06-23End: 2027-05-01Target: 359Updated: 2026-01-30

Related Papers

PregInPoxVac maternal protocol: a phase 3 trial evaluating maternal immunogenicity and safety of the MVA-BN vaccine in the Democratic Republic of the Congo.

2026-07-28